The partnership leverages Salipro Biotech’s Salipro platform technology, which stabilizes membrane proteins in their native forms, enabling their use in drug discovery programs. Boehringer Ingelheim will conduct biophysical and structural studies, including cryo-electron microscopy (cryoEM), on Boehringer pipeline targets enabled by the Salipro-technology to identify potential therapeutic candidates.

Under the terms of the agreement, Salipro Biotech will receive research payments, option payments and is eligible for downstream success-based milestone payments based on developmental results generated by Boehringer Ingelheim under this collaboration.

“We are excited to collaborate with the innovative teams at Boehringer Ingelheim,” says Jens Frauenfeld, CEO of Salipro Biotech. “By combining our Salipro platform technology with Boehringer Ingelheim’s expertise in biophysical and structural studies, we enable new possibilities in drug discovery and development.”